全视网膜光凝与雷珠单抗治疗增殖性糖尿病视网膜病变:视力与水肿结局的相关因素
该研究为Protocol S随机多中心临床试验的事后分析,纳入完成2年随访的328只眼或无视力损害性中心受累DME的302只眼,比较雷珠单抗与PRP治疗增殖性糖尿病视网膜病变。雷珠单抗组平均视力改善且未识别出与视力或DME结局相关的基线因素;PRP组中较高HbA1c、更严重DR和较高平均动脉压与视力改善较差相关,较高HbA1c、更严重DR及黄斑中心500μm内囊样异常与视力损害性中心受累DME发生风险增加相关。
要点
- 雷珠单抗组平均视力改善,未识别出与视力或DME结局相关的基线因素。
- PRP组中HbA1c每升高1%,视力变化减少0.6字母(95%CI -1.2至-0.1)。
- PRP组中高危PDR或更严重者较高危以下者视力变化差2.8字母。
核心结论
- PRP治疗眼中,较高HbA1c和更严重糖尿病视网膜病变与视力改善较少及视力损害性中心受累DME风险增加相关。
- 雷珠单抗治疗眼中,平均视力获得改善,未识别出与视力或中心受累DME结局相关的基线特征。
研究设计与样本
- 随机多中心临床试验数据的事后分析。
- 纳入完成2年随访的328只眼,或无基线视力损害性中心受累DME的302只眼,来自DRCR Network Protocol S。
- 干预为玻璃体腔注射雷珠单抗0.5 mg/0.05 ml或全视网膜光凝。
主要发现
- 雷珠单抗组经多变量模型选择并调整基线视力和中心子域厚度后,未识别出与视力变化或视力损害性中心受累DME发生相关的因素。
- PRP组中,HbA1c每升高1%,视力变化减少0.6字母(95%CI -1.2至-0.1字母;连续P=0.03)。
- PRP组中,高危PDR或更严重者与中度PDR或更好者相比,视力变化差2.8字母(95%CI -5.5至-0.2字母;连续P=0.003)。
- PRP组中,平均动脉压≥100 mmHg者与<100 mmHg者相比,视力变化差2.0字母(95%CI -4.6至0.5字母;连续P=0.009)。
- PRP组中,视力损害性中心受累DME发生风险:HbA1c每升高1%,HR 1.31(95%CI 1.13-1.52;连续P<0.001);高危PDR或更严重者与中度PDR或更好者相比,HR 1.46(95%CI 0.73-2.92;连续P=0.03);黄斑中心500μm内囊样异常存在时,HR 2.90(95%CI 1.35-6.24;P=0.006)。
临床怎么用
- 对于采用PRP管理的增殖性糖尿病视网膜病变眼,较高HbA1c水平、更严重糖尿病视网膜病变及黄斑中心500μm内囊样异常与较差的视力结局或较高的视力损害性中心受累DME风险相关。
- 对于采用雷珠单抗管理的增殖性糖尿病视网膜病变眼,平均视力获得改善,未识别出与视力或中心受累DME结局相关的基线特征。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify baseline factors associated with change in visual acuity or development of vision-impairing central-involved diabetic macular edema (DME) over 2 years when treating proliferative diabetic retinopathy (PDR) with ranibizumab or panretinal photocoagulation (PRP). DESIGN: Post hoc analyses of randomized, multicenter clinical trial data. PARTICIPANTS: Eyes completing the 2-year visit (n = 328) or without vision-impairing central-involved DME at baseline (n = 302) in Diabetic Retinopathy Clinical Research Network Protocol S. METHODS: Intravitreous ranibizumab (0.5 mg/0.05 ml) or PRP. MAIN OUTCOME MEASURES: Change in visual acuity (area under the curve) and development of vision-impairing (20/32 or worse) central-involved DME over 2 years. RESULTS: After multivariable model selection with adjustment for baseline visual acuity and central subfield thickness, no factors were identified as associated with change in visual acuity or development of vision-impairing central-involved DME within the ranibizumab group. In the PRP group, worse change in visual acuity was more likely with higher hemoglobin A1c level (-0.6 letters per 1% increase; 95% confidence interval [CI], -1.2 to -0.1 letters; continuous P = 0.03), more severe diabetic retinopathy (difference between high-risk PDR or worse vs. moderate PDR or better, -2.8 letters [95% CI, -5.5 to -0.2 letters]; continuous P = 0.003), and higher mean arterial pressure (difference between ≥100 mmHg vs. <100 mmHg, -2.0 letters [95% CI, -4.6 to 0.5 letters]; continuous P = 0.009). Development of vision-impairing central-involved DME was more likely with higher hemoglobin A1c level (hazard ratio [HR] per 1% increase, 1.31 [95% CI, 1.13-1.52]; continuous P < 0.001), more severe diabetic retinopathy (HR for high-risk PDR or worse vs. moderate PDR or better, 1.46 [95% CI, 0.73-2.92]; continuous P = 0.03), and the presence of cystoid abnormalities within 500 μm of the macula center (HR, 2.90 [95% CI, 1.35-6.24]; P = 0.006). CONCLUSIONS: For eyes managed with PRP, higher hemoglobin A1c level and more severe diabetic retinopathy were associated with less vision improvement and an increased risk of vision-impairing central-involved DME developing. When managing PDR with ranibizumab, eyes gained vision, on average, with no baseline characteristics identified as associated with visual acuity or central-involved DME outcomes.
引用
- Bressler SB, Beaulieu WT, Glassman AR, et al. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes. Ophthalmology. 2018. PMID: 29980333. doi:10.1016/j.ophtha.2018.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。